Scarica l'app Stockscreener
547.74
2.40%
12.83
Pre-mercato:
548.86
1.12
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals (REGN) Announces Key Decisions from 20 - GuruFocus
Regeneron Shareholders Approve Key Proposals at 2025 Meeting - TipRanks
Grove Bank & Trust Has $514,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Exchange Traded Concepts LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Factory Mutual Insurance Co. Buys 8,200 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Steps Back, TTAM Aims To Reclaim 23andMe - Finimize
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive
Regeneron (REGN) Exits 23andMe Bidding War - GuruFocus
Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer - Seeking Alpha
PKO Investment Management Joint Stock Co Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Schaper Benz & Wise Investment Counsel Inc. WI - MarketBeat
Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe - MarketScreener
Breakthroughs in Uveitis Treatment Market Drive Global Demand - openPR.com
Harbor Capital Advisors Inc. Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
23andme founder-led group outbids Regeneron for company - BioWorld MedTech
Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer - Reuters
Regeneron Pharmaceuticals says declined to submit new bid on 23andMe exceeding original $256 mln - MarketScreener
Fifth Third Bancorp Sells 952 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target - MSN
Anne Wojcicki overcomes Regeneron in 23andMe assets battle - The Pharma Letter
Anne Wojcicki’s Nonprofit Tops Bid for 23andMe Assets - Contract Pharma
Patient Data Revolution: New Blockchain Platform Challenges Regeneron's $600M 23andMe Data Grab - Stock Titan
BDF Gestion Has $2.82 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dupixent demonstrated superiority over Xolair in chronic rhinosinusitis - The Pharma Letter
Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million - MarketScreener
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Warther Private Wealth LLC - MarketBeat
Mn Services Vermogensbeheer B.V. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Silver Scott Health, Inc. Unveils Health Trust NFT to Empower Patient Data Control in Response to Regeneron's $600 Million 23andMe Bid - The Globe and Mail
Sanofi, Regeneron Say Dupixent Outperforms Xolair in Phase 4 Respiratory Trial - marketscreener.com
RMR Wealth Builders Acquires Shares of 2,141 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Osprey Private Wealth LLC Makes New $2.24 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Pallas Capital Advisors LLC Invests $426,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi: positive data in chronic rhinosinusitis - marketscreener.com
Smithbridge Asset Management Inc. DE Invests $3.41 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Leerink Partnrs Issues Negative Forecast for REGN Earnings - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by NorthCrest Asset Manangement LLC - MarketBeat
Sanofi, Regeneron Report Encouraging Results from Head-to-head Respiratory Study - MarketScreener
Regeneron (REGN) and Sanofi's Dupixent Shows Superior Results in Key Phase 4 Trial | REGN Stock News - GuruFocus
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - GlobeNewswire
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe … - GlobeNewswire Inc.
Dupixent Outperforms Xolair in First-Ever Head-to-Head Trial for Nasal Polyps | REGN Stock News - Stock Titan
Asio Capital LLC Has $2.53 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Greenwood Capital Associates LLC Invests $5.35 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis - Insider Monkey
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Wedmont Private Capital Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Handelsbanken Fonder AB - MarketBeat
Assenagon Asset Management S.A. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
New England Research & Management Inc. Invests $384,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | - GuruFocus
Regeneron’s SWOT analysis: stock faces eylea challenges, pipeline potential - Investing.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Miracle Mile Advisors LLC - MarketBeat
Tounjian Advisory Partners LLC Invests $662,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Research Analysts Offer Predictions for REGN FY2026 Earnings - MarketBeat
23andMe co-founder Anne Wojcicki has bought back the company - NewsBytes
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm - MSN
Atwood & Palmer Inc. Has $26.62 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Anne Wojcicki to buy back 23andMe and its data for $305 million - MSN
Regeneron requests bundling ban after trial win - Global Competition Review
Former 23andMe CEO wins bidding war against Regeneron - FirstWord
23andMe's founder Anne Wojcicki wins bid for DNA testing firm - MSN
23andMe founder buys back genetic testing company in second auction - Financial Times
2.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):